Literature DB >> 8748677

Neurotensin peptides antagonistically regulate postsynaptic dopamine D2 receptors in rat nucleus accumbens: a receptor binding and microdialysis study.

X M Li1, L Ferraro, S Tanganelli, W T O'Connor, U Hasselrot, U Ungerstedt, K Fuxe.   

Abstract

An in vitro receptor binding and in vivo microdialysis study was performed to further investigate the modulation of dopamine (DA) D2 receptors by neurotensin (NT) peptides. Saturation experiments with the D2 agonist [3H]NPA (N-propylnorapomorphine) showed that 10 nM of NT, 10 nM of neuromedin N (NN) and 1 nM of the C-terminal NT-(8-13) fragment significantly increased the KD values by 125%, 181%, and 194%, respectively without significantly affecting the Bmax value of the [3H]NPA binding sites in coronal sections of rat ventral forebrain mainly containing the nucleus accumbens (Acb) and the olfactory tubercle. In line with the previous findings that NT can increase GABA release in the Acb and that NT receptors are not found on DA terminals in this brain region, the present in vivo microdialysis study demonstrated that local perfusion of NT (1 nM) counteracted the D2 agonist pergolide (2 mu M) induced inhibition of GABA, but not of DA release in the rat Acb. This result indicates that NT counteracts the D2 agonist induced inhibition of GABA release in the rat Acb, via an antagonistic postsynaptic NT/D2 receptor interaction as also suggested by the inhibitory regulation of D2 receptor affinity in the Acb by the NT peptides demonstrated in the present receptor binding experiments. Thus, the neuroleptic and potential antipsychotic profile of the NT peptides may involve an antagonistic NT/D2 receptor regulation in the ventral striatum.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8748677     DOI: 10.1007/bf01276508

Source DB:  PubMed          Journal:  J Neural Transm Gen Sect


  32 in total

1.  Potentiation by thiorphan and bestatin of the naloxone-insensitive analgesic effects of neurotensin and neuromedin n.

Authors:  A Coquerel; I Dubuc; P Kitaegi; J Costentin
Journal:  Neurochem Int       Date:  1988       Impact factor: 3.921

Review 2.  Fitting curves to data using nonlinear regression: a practical and nonmathematical review.

Authors:  H J Motulsky; L A Ransnas
Journal:  FASEB J       Date:  1987-11       Impact factor: 5.191

3.  Neurotensin in vitro markedly reduces the affinity in subcortical limbic 3H-N-propylnorapomorphine binding sites.

Authors:  L F Agnati; K Fuxe; F Benfenati; N Battistini
Journal:  Acta Physiol Scand       Date:  1983-12

4.  Calcium-dependent release of neuromedin N and neurotensin from mouse hypothalamus.

Authors:  P Kitabgi; F De Nadai; J C Cuber; I Dubuc; D Nouel; J Costentin
Journal:  Neuropeptides       Date:  1990-02       Impact factor: 3.286

5.  Cloning and sequence analysis of cDNA for the canine neurotensin/neuromedin N precursor.

Authors:  P R Dobner; D L Barber; L Villa-Komaroff; C McKiernan
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

6.  Strong effects of NT/NN peptides on DA D2 receptors in rat neostriatal sections.

Authors:  X M Li; P B Hedlund; K Fuxe
Journal:  Neuroreport       Date:  1994-08-15       Impact factor: 1.837

7.  The rat gene encoding neurotensin and neuromedin N. Structure, tissue-specific expression, and evolution of exon sequences.

Authors:  E Kislauskis; B Bullock; S McNeil; P R Dobner
Journal:  J Biol Chem       Date:  1988-04-05       Impact factor: 5.157

8.  The effects of neurotensin on GABA and acetylcholine release in the dorsal striatum of the rat: an in vivo microdialysis study.

Authors:  W T O'Connor; S Tanganelli; U Ungerstedt; K Fuxe
Journal:  Brain Res       Date:  1992-02-28       Impact factor: 3.252

9.  Dopamine D1 receptors are involved in the modulation of D2 receptors induced by cholecystokinin receptor subtypes in rat neostriatal membranes.

Authors:  X M Li; P B Hedlund; L F Agnati; K Fuxe
Journal:  Brain Res       Date:  1994-07-11       Impact factor: 3.252

10.  Neuromedin N mimics the actions of neurotensin in the ventral tegmental area but not in the nucleus accumbens.

Authors:  P W Kalivas; R Richardson-Carlson; P Duffy
Journal:  J Pharmacol Exp Ther       Date:  1986-09       Impact factor: 4.030

View more
  13 in total

1.  Cross-receptor interactions between dopamine D2L and neurotensin NTS1 receptors modulate binding affinities of dopaminergics.

Authors:  Susanne Koschatzky; Nuska Tschammer; Peter Gmeiner
Journal:  ACS Chem Neurosci       Date:  2011-04-11       Impact factor: 4.418

Review 2.  The role of neurotensin in central nervous system pathophysiology: what is the evidence?

Authors:  Fannie St-Gelais; Claudia Jomphe; Louis-Eric Trudeau
Journal:  J Psychiatry Neurosci       Date:  2006-07       Impact factor: 6.186

Review 3.  Neurotensin agonists: potential in the treatment of schizophrenia.

Authors:  Mona Boules; Amanda Shaw; Paul Fredrickson; Elliott Richelson
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

4.  Hyperactivity of the dopaminergic system in NTS1 and NTS2 null mice.

Authors:  Yanqi Liang; Mona Boules; Zhimin Li; Katrina Williams; Tomofumi Miura; Alfredo Oliveros; Elliott Richelson
Journal:  Neuropharmacology       Date:  2010-03-06       Impact factor: 5.250

5.  Chronic, but not acute, dosing of antipsychotic drugs alters neurotensin binding in rat brain regions.

Authors:  P E Holtom; P L Needham; G W Bennett; S Aspley
Journal:  Br J Pharmacol       Date:  2000-11       Impact factor: 8.739

6.  Activation of neurotensin receptor type 1 attenuates locomotor activity.

Authors:  Chelsea A Vadnie; David J Hinton; Sun Choi; YuBin Choi; Christina L Ruby; Alfredo Oliveros; Miguel L Prieto; Jun Hyun Park; Doo-Sup Choi
Journal:  Neuropharmacology       Date:  2014-06-11       Impact factor: 5.250

Review 7.  Receptor-receptor interactions as studied with microdialysis. Focus on NTR/D2 interactions in the basal ganglia.

Authors:  T Antonelli; M C Tomasini; K Fuxe; L F Agnati; S Tanganelli; L Ferraro
Journal:  J Neural Transm (Vienna)       Date:  2006-09-19       Impact factor: 3.575

8.  Reversal of quinpirole inhibition of ventral tegmental area neurons is linked to the phosphatidylinositol system and is induced by agonists linked to G(q).

Authors:  Sudarat Nimitvilai; Maureen A McElvain; Devinder S Arora; Mark S Brodie
Journal:  J Neurophysiol       Date:  2012-04-04       Impact factor: 2.714

9.  Extrasynaptic neurotransmission in the modulation of brain function. Focus on the striatal neuronal-glial networks.

Authors:  Kjell Fuxe; Dasiel O Borroto-Escuela; Wilber Romero-Fernandez; Zaida Diaz-Cabiale; Alicia Rivera; Luca Ferraro; Sergio Tanganelli; Alexander O Tarakanov; Pere Garriga; José Angel Narváez; Francisco Ciruela; Michele Guescini; Luigi F Agnati
Journal:  Front Physiol       Date:  2012-06-04       Impact factor: 4.566

10.  Diverse roles of neurotensin agonists in the central nervous system.

Authors:  Mona Boules; Zhimin Li; Kristin Smith; Paul Fredrickson; Elliott Richelson
Journal:  Front Endocrinol (Lausanne)       Date:  2013-03-22       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.